Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 3,553 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluids Clear all

Conditions: Norovirus Acute Gastroenteritis
Interventions: mRNA-1403, mRNA-1405, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,407 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 14
States / cities: Long Beach, California • Longmont, Colorado • Hollywood, Florida + 11 more

Conditions: Myotonic Dystrophy Type 2, Myotonic Dystrophy Type 1
Interventions: Non-interventional study; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 30 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Otitis Media
Interventions: Cranial osteopathic manipulative treatment., Echinacea purpurea, Sham osteopathic manipulative treatment, "Echinacea purpurea" placebo; Procedure · Dietary Supplement
Lead sponsor: University of Arizona; Other
Eligibility: 12 Months to 60 Months
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2002
U.S. locations: 3
States / cities: Tucson, Arizona

Conditions: Dehydration in Children, Dehydration
Interventions: LifeFlow; Device
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 1 Month to 18 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: SARS CoV-2
Interventions: Human Amniotic Fluid; Biological
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Colonic Diseases
Interventions: Clear liquids, Low residue breakfast and lunch; Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Caffeine, Warfarin, Omeprazole, Metoprolol, Midazolam Hydrochloride; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Little Rock, Arkansas • Rogers, Arkansas • San Diego, California + 5 more

Conditions: Oral Mucositis
Interventions: amlexanox, Vehicle rinse; Drug
Lead sponsor: Access Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 12
States / cities: Mobile, Alabama • Little Rock, Arkansas • Bakersfield, California + 9 more

Conditions: Urinary Incontinence, Pelvic Organ Prolapse
Interventions: Retrograde bladder fill, spontaneous void; Procedure · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: HIV, ICL, Healthy Volunteers
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1994
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Asthma
Interventions: PLACEBO, MEDI528 9 mg/kg; Other · Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 4
States / cities: Boston, Massachusetts • St Louis, Missouri • Winston-Salem, North Carolina + 1 more

Conditions: Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
Interventions: ONL1204 Opthalmic solution, Avacincaptad Pegol intravitreal solution, Sham; Drug · Other
Lead sponsor: ONL Therapeutics; Industry
Eligibility: 55 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 56
States / cities: Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 50 more

Conditions: Fungal Infection
Interventions: Placebo, Rezafungin; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Nicotine Dependence
Interventions: Nicotine, Vaporizer Device, Salt-HIgh Nicotine Unflavored (Product B), Free-Low Nicotine Tobacco Flavored (Product C), Salt-High Nicotine Tobacco Flavored (Product D); Drug · Device
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 21 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Pancreatic Disease
Interventions: ChiRhoStim, Placebo; Drug
Lead sponsor: ChiRhoClin, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Urinary Retention
Interventions: Retained fluid, Emptied fluid; Procedure
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions: Biospecimen Collection, Bone Marrow Aspirate, Cyclophosphamide, Cyclosporine, Diagnostic Imaging Testing, Echocardiography Test, Fludarabine Phosphate, Multigated Acquisition Scan, Mycophenolate Mofetil, Survey Administration, Thiotepa, Total-Body Irradiation, Umbilical Cord Blood Transplantation; Procedure · Drug · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 6 Months to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Infertility
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1,235 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Melanoma
Interventions: CP 870,893, Peptides, Oncovir poly IC:LC; Drug · Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer, Hereditary Breast and Ovarian Cancer Syndrome, Breast Implant; Complications
Interventions: Insertion of Tissue Expander with Fluid Reservoir; Device
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Charcot-Marie-Tooth Disease Type 1A
Interventions: PXT3003 dose 1, PXT3003 dose 2, placebo; Drug
Lead sponsor: Pharnext S.C.A.; Other
Eligibility: 16 Years to 65 Years
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 11
States / cities: Los Angeles, California • New Britain, Connecticut • Gainesville, Florida + 8 more

Conditions: Postural Tachycardia Syndrome
Interventions: Autonomic Function Testing, Posture Study, Measurement of Total Blood Volume, Exercise Capacity Test; Other · Procedure
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Acute Myelogenous Leukemia, Refractory Acute Myelogenous Leukemia
Interventions: Allopurinol, Fludarabine, Total body irradiation, Cyclophosphamide, Levetiracetam, Busulfan, Umbilical Cord Blood Transplantation, Interleukin-2; Drug · Radiation · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 2 Years to 45 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unusual Cancers of Childhood
Interventions: anti-thymocyte globulin, filgrastim, busulfan, carmustine, cyclophosphamide, cyclosporine, cytarabine, etoposide, fludarabine phosphate, melphalan, methotrexate, methylprednisolone, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: Up to 60 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2

Echinacea Purpurea and Osteopathy in Children With Recurrent Otitis Media

LifeFlow Fluid Study- Non- Critical Pediatric Patients Having a Trans Abdominal Ultrasound

Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients

The Impact of Diet Liberalization on Bowel Preparation for Colonoscopy

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

Study to Determine the Effects Treatment With Amlexanox 0.5% Oral Rinse Solution on Oral Mucositis Associated With Radiation Therapy for Cancer of the Head and Neck Region

Voiding Assessment Based on Minimum Spontaneous Void of 150 mL Compared to Retrograde Fill Method After Female Pelvic Floor Reconstructive Surgery

Tissue Biopsy and Imaging Studies in HIV-Infected Patients

A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

Safety and Pharmacokinetics of Rezafungin

Pharmacokinetics, Subjective Effects, and Abuse Liability of Nicotine Salt-Based Vaping Products With Tobacco or Unflavored E-liquids, SALTVAPE Study

A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers

Post Hysterectomy Benefits of Retained Cystoscopy Fluid

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Infertility Markers in Serum, Urine, and Follicular Fluid

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

Tissue Expansion in Breast Reconstruction Without Drains

Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)

Aldosterone & Sodium Regulation in Postural Tachycardia Syndrome - Screening

T-Cell Depleted Double UCB for Refractory AML

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer